

The logo for PHARMAC (Te Pātaka Whaioranga) is a white circle containing the text "PHARMAC" in a bold, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, all-caps sans-serif font below it. The background of the entire page is a grey-to-white gradient with a large, intricate white pattern of overlapping, curved lines that resemble a stylized maze or a complex geometric design.

PHARMAC
TE PĀTAKA WHAIORANGA

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Update

March 2023

Contents

Summary of Pharmac decisions effective 1 March 2023	3
Tender News	6
Looking Forward	7
Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023	8
New Listings.....	22
Changes to Restrictions, Chemical Names and Presentations	25
Changes to Subsidy and Manufacturer’s Price.....	30
Delisted Items	32
Items to be Delisted	34
Index.....	36

Summary of Pharmac decisions

EFFECTIVE 1 MARCH 2023

New listings (pages 22-24)

- Calcium carbonate (Calcium Carbonate PAI) oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – subsidy by endorsement
- Hydrocortisone acetate (Colifoam) rectal foam 10%, CFC-Free (14 applications), 15 g OP
- Liraglutide (Victoza) inj 6 mg per ml, 3 ml prefilled pen – Special Authority – Retail pharmacy, maximum of 9 inj per prescription, not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist, maximum of 1 pack of 3 prefilled pens will be funded per month
- Folic acid (Folic Acid Viatris) tab 5 mg
- Midodrine (Midodrine Medsurge) tab 2.5 mg and 5 mg – Special Authority – Retail pharmacy
- Metoprolol tartrate (Metoprolol IV Viatris) inj 1 mg per ml, 5 ml vial
- Pravastatin (Pravastatin Viatris) tab 20 mg
- Simvastatin (Simvastatin Viatris) tab 40 mg
- Hydrocortisone (Noumed) crm 1%, 500 g – only on a prescription
- Ethinyloestradiol with levonorgestrel tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets (Lo-Oralcon 20 ED) and tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets (Oralcon 30 ED) – up to 112 tab available on a PSO
- Clindamycin (Hameln) inj 150 mcg per ml, 4 ml ampoule
- Pethidine hydrochloride (Noumed Pethidine) tab 50 mg – only on a controlled drug form, no patient co-payment payable and Safety Medicine
- Ondansetron (Periset) tab 4 mg and 8 mg
- Clozapine (Clozaril) tab 25 mg and 100 mg, 50 tab packs – Hospital pharmacy [HP4], Safety Medicine and new Pharmacodes
- Octreotide (Octreotide GH) inj 100 mcg per ml, 1 ml ampoule – s29 and wastage claimable
- Pharmacy services (BSF Ticagrelor Sandoz, BSF Vebulis and BSF Celapram) brand switch fee – may only be claimed once per patient
- Influenza vaccine (Afluria Quad Junior (2023 formulation)) inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) – Xpharm, access criteria apply
- Influenza vaccine (Afluria Quad (2023 formulation)) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – only on a prescription, No patient co-payment payable and access criteria apply
- Rotavirus oral vaccine (Rotarix) oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube – Xpharm, access criteria apply

Summary of Pharmac decisions – effective 1 March 2023 (continued)

Changes to restrictions (pages 25-29)

- Sodium alginate (Gaviscon Extra Strength) tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg – peppermint flavour – brand name change
- Insulin syringes and needles – amended note
- Glycerol (Lax-suppositories Glycerol) suppos 2.8/4.0 g – amended presentation description
- Ticagrelor (Ticagrelor Sandoz) tab 90 mg – addition of Brand Switch Fee
- Quinapril tab 5 mg (Arrow-Quinapril 5), tab 10 mg (Arrow-Quinapril 10) and tab 20 mg (Arrow-Quinapril 20) – reinstate stat dispensing
- Propranolol (Drofate) tab 10 mg – reinstate stat dispensing
- Iloprost (Vebulis) nebuliser soln 10 mcg per ml, 2 ml – addition of Brand Switch Fee
- Zoledronic acid (Zoledronic acid Mylan and Zoledronic acid Viartis) inj 4 mg per 5 ml, vial – Special Authority criteria removed
- Clindamycin (Hameln and Dalacin C) inj 150 mg per ml, 4 ml ampoule – amended presentation description
- Zoledronic acid inj 0.05 mg per ml, 100 ml, bag (Zoledronic Acid Viartis and Zoledronic-US) and inj 0.05 mg per ml, 100 ml, vial (Aclasta) – Special Authority criteria removed
- Citalopram hydrobromide (Celapram) tab 20 mg – addition of Brand Switch Fee
- Disulfiram (Antabuse) tab 200 mg – removal of s29 and wastage claimable
- Meningococcal B multicomponent vaccine (Bexsero) inj 175 mcg per 0.5 ml prefilled syringe – amended restriction criteria

Increased subsidy (pages 30-31)

- Dipyridamole (Pytazen SR) tab long-acting 150 mg
 - Compound electrolytes with glucose [dextrose] (Pedialyte – Bubblegum) soln with electrolytes (2 x 500 ml), 1,000 ml OP
 - Flecainide acetate (Tambacor) inj 10 mg per ml, 15 ml ampoule
 - Glyceryl trinitrate (Nitrolingual Pump Spray) oral pump spray, 400 mcg per dose, 250 dose OP
 - Tetracycline (Accord) tab 250 mg
 - Pyridostigmine bromide (Mestinon) tab 60 mg
 - Theophylline tab long-acting 250 mg (Nuelin-SR) and oral liq 80 mg per 15 ml, 500 ml (Nuelin)
-

Summary of Pharmac decisions – effective 1 March 2023 (continued)

- Mask for spacer device (e-chamber Mask) small
- Spacer device (e-chamber Turbo) 220 ml (single patient)
- Spacer device (e-chamber La Grande) 510 ml (single patient)

Decreased subsidy (page 30)

- Flecainide acetate (Flecainide Controlled Release Teva) cap long-acting 100 mg and 200 mg
- Roxithromycin (Arrow-Roxithromycin) tab 150 mg and 300 mg

Increased price but not subsidy (page 30)

- Sodium alginate (Gaviscon Extra Strength) tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg – peppermint flavour
- Econazole nitrate (Pevaryl) crm 1%, 20 g OP and foaming soln 1%, 10 ml sachet
- Wool fat with mineral oil (DP Lotion) lotn hydrous 3% with mineral oil, 1,000 ml and 250 ml OP

Tender News

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) changes – effective 1 April 2023

Chemical Name	Presentation; Pack size	PSS/SSS	PSS/SSS brand (and supplier)
Aciclovir	Tab dispersible 400 mg; 56 tab	PSS	Lovir (Douglas)
Aciclovir	Tab dispersible 800 mg; 35 tab	PSS	Lovir (Douglas)
Azathioprine	Tab 25 mg; 60 tab	PSS	Azamun (Douglas)
Cefaclor monohydrate	Cap 250 mg; 100 cap	PSS	Ranbaxy Cefaclor (Douglas)
Cefaclor monohydrate	Grans for oral liq 125 mg per 5 ml; 100 ml	PSS	Ranbaxy Cefaclor (Douglas)
Cefalexin	Cap 250 mg; 20 cap	PSS	Cephalexin ABM (Boucher)
Cefalexin	Cap 500 mg; 20 cap	PSS	Cephalexin ABM (Boucher)
Ceftriaxone	Inj 500 mg; 1 inj	PSS	Ceftriaxone-AFT (AFT)
Ceftriaxone	Inj 1 g vial; 5 inj	PSS	Ceftriaxone-AFT (AFT)
Chlortalidone [Chlorthalidone]	Tab 25 mg; 50 tab	PSS	Hygroton (AFT)
Clotrimazole	Vaginal crm 1% with applicators; 35 g OP	PSS	Clomazol (Multichem)
Clotrimazole	Vaginal crm 2% with applicators; 20 g OP	PSS	Clomazol (Multichem)
Clotrimazole	Crn 1%; 20 g OP	PSS	Clomazol (Multichem)
Codeine phosphate	Tab 30 mg; 100 tab	PSS	Noumed (Noumed)
Codeine phosphate	Tab 60 mg; 100 tab	PSS	Noumed (Noumed)
Hydrocortisone	Crn 1%, 30 g OP	PSS	Ethics (Multichem)
Intra-uterine device	IUD 29.1 mm length x 23.2 mm width; 1 dev	PSS	Choice TT380 Short (Boucher)
Intra-uterine device	IUD 33.6 mm length x 29.9 mm width; 1 dev	PSS	Choice TT380 Standard (Boucher)
Intra-uterine device	IUD 35.5 mm length x 19.6 mm width; 1 dev	PSS	Choice Load 375 (Boucher)
Lactulose	Oral liq 10 g per 15 ml; 500 ml	PSS	Laevolac (Douglas)
Levomepromazine hydrochloride	Inj 25 mg per ml, 1 ml ampoule; 10 inj	PSS	Wockhardt (Max Health)
Morphine sulphate	Cap long-acting 10 mg; 10 cap	PSS	m-Eslon (Multichem)
Morphine sulphate	Cap long-acting 30 mg; 10 cap	PSS	m-Eslon (Multichem)
Morphine sulphate	Cap long-acting 60 mg; 10 cap	PSS	m-Eslon (Multichem)
Morphine sulphate	Cap long-acting 100 mg; 10 cap	PSS	m-Eslon (Multichem)
Paracetamol	Oral liq 250 mg per ml, 200 ml	PSS	Pamol (Aspen)
Posaconazole	Tab modified-release 100 mg	PSS	Posaconazole Juno (Juno)
Sertraline	Tab 50 mg; 30 tab	PSS	Setrona (Douglas)
Sertraline	Tab 100 mg' 30 tab	PSS	Setrona (Douglas)

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) changes
– effective 1 April 2023 (continued)

Chemical Name	Presentation; Pack size	PSS/SSS	PSS/SSS brand (and supplier)
Sunscreens, proprietary	Lotn; 200 g OP	PSS	Marine Blue Lotion SPF lotn 50+ (Boucher)
Tetrabenazine	Tab 25 mg; 112 tab	PSS	Motetis (Douglas)
Thiamine hydrochloride	Tab 50 mg; 100 tab	PSS	Thiamine multichem (Multichem)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Decisions for implementation 1 April 2023

- Chloramphenicol (Chlorsig) eye drops 0.5%, 10 ml OP – new listing
- Enalapril maleate (Acetec) tab 5 mg, 10 mg and 20 mg – new listing
- Sumatriptan (Clustran) inj 12 mg per ml, 0.5 ml prefilled pen – new listing

Possible decisions for future implementation 1 April 2023

- Atezolizumab inj 60 mg per ml, 20 ml vial (Tecentriq) and inj 1 mg for ECP (Baxter) – new listing with Special Authority and PCT only
- Elexacaftor with tezacaftor, ivacaftor and ivacaftor (Trikafta) tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg and ivacaftor 75 mg and tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg and ivacaftor 150 mg – new listing with Special Authority and PCT only
- Pembrolizumab inj 25 mg per ml, 4 ml vial (Keytruda) and inj 1 mg for ECP (Baxter) – amend Special Authority criteria and subsidy decrease for inj 1 mg for ECP (Baxter)

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Acarbose	Tab 50 mg & 100 mg	Accarb	2024
Acetylcysteine	Inj 200 mg per ml, 10 ml ampoule	Martindale Pharma	2024
Aciclovir	Tab dispersible 200 mg Eye oint 3%, 4.5 g OP	Lovir VirusPOS	2025 2024
Acitretin	Cap 10 mg & 25 mg	Novatretin	2023
Adalimumab (Amgevita)	Inj 20 mg per 0.4 ml prefilled syringe, inj 40 mg per 0.8 ml prefilled syringe & inj 40 mg per 0.8 ml prefilled pen	Amgevita	31/07/2026
Allopurinol	Tab 100 mg & 300 mg	DP-Allopurinol	2023
Ambrisentan	Tab 5 mg & 10 mg	Ambrisentan Mylan	2023
Amiodarone hydrochloride	Inj 50 mg per ml, 3 ml ampoule Tab 100 mg & 200 mg	Max Health Aratac	2025
Amitriptyline	Tab 10 mg, 25 mg & 50 mg	Arrow-Amitriptyline	2023
Amlodipine	Tab 2.5 mg, 5 mg & 10 mg	Vasorex	2023
Amorolfine	Nail soln 5%, 5 ml OP	MycoNail	2023
Amoxicillin	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Alphamox 125 Alphamox 250	2023
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg	Curam Duo 500/125	2023
Anastrozole	Tab 1 mg	Anatrole	2023
Apomorphine hydrochloride	Inj 10 mg per ml, 5 ml ampoule Inj 10 mg per ml, 2 ml ampoule	Movapo	2023
Aprepitant	Cap 2 x 80 mg and 1 x 125 mg	Emend Tripack	2024
Aqueous cream	Crn, 500 g	GEM Aqueous Cream	2024
Ascorbic acid	Tab 100 mg	CVite	2025
Atenolol	Tab 50 mg & 100 mg	Mylan Atenolol	2024
Atorvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Lorstat	2024
Atropine sulphate	Inj 600 mcg per ml, 1 ml ampoule Eye drops 1%, 15 ml OP	Martindale Atropt	2024 2023
Azathioprine	Tab 50 mg	Azamun	2025
Azithromycin	Tab 500 mg	Zithromax	2024
Bacillus calmette-guerin vaccine	Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent	BCG Vaccine	2024
Baclofen	Inj 2 mg per ml, 5 ml ampoule	Medsurge	2024
Bendroflumethiazide [Bendrofluazide]	Tab 2.5 mg & 5 mg	Arrow- Bendrofluazide	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Benzatropine mesylate	Inj 1 mg per ml, 2 ml	Phebra	2023
Benzylpenicillin sodium [Penicillin G]	Inj 600 mg (1 million units) vial	Sandoz	2023
Betahistine dihydrochloride	Tab 16 mg	Serc	2023
Betamethasone dipropionate	Crn & oint 0.05%, 50 g OP	Diprosone	2023
Betamethasone dipropionate with calcipotriol	Oint 500 mcg with calcipotriol 50 mcg per g, 30 g OP Gel 500 mcg with calcipotriol 50 mcg per g, 60 g OP	Daivobet	2024
Betamethasone valerate	Lotn 0.1%, 50 ml OP Oint 0.1%, 50 g OP Crn 0.1%, 50 g OP Scalp app 0.1%, 100 ml OP	Betnovate Beta Ointment Beta Cream Beta Scalp	2024
Bicalutamide	Tab 50 mg	Binarex	2023
Bimatoprost	Eye drops 0.03%, 3 ml OP	Bimatoprost Multichem	2024
Bisacodyl	Tab 5 mg Suppos 10 mg	Bisacodyl Viatrix Pharmacy Health Lax-suppositories	2025 2024
Bisoprolol fumarate	Tab 2.5 mg, 5 mg & 10 mg	Bisoprolol Mylan	2023
Bosentan	Tab 62.5 mg & 125 mg	Bosentan Dr Reddy's	2024
Brimonidine tartrate	Eye drops 0.2%, 5 ml OP	Arrow-Brimonidine	2024
Brinzolamide	Eye drops 1%, 5 ml OP	Azopt	2024
Budesonide	Metered aqueous nasal spray, 50 mcg & 100 mcg per dose, 200 dose OP	SteroClear	2023
Bupropion hydrochloride	Tab modified-release 150 mg	Zyban	2023
Bezafibrate	Tab 200 mg Tab long-acting 400 mg	Bezalip Bezalip Retard	2024
Buprenorphine with naloxone	Tab sublingual 2 mg with naloxone 0.5 mg & 8 mg with naloxone 2 mg	Buprenorphine Naloxone BNM	2025
Buspirone hydrochloride	Tab 5 mg & 10 mg	Buspirone Viatrix	2024
Calamine	Crn, aqueous, BP, 100 g	Calamine-AFT	2024
Calcitriol	Cap 0.25 mcg & 0.5 mcg	Calcitriol-AFT	2025
Calcium carbonate	Tab 1.25 g (500 mg elemental)	Calci-Tab 500	2023
Candesartan cilexetil	Tab 4 mg, 8 mg, 16 mg & 32 mg	Candestar	2024
Capsaicin	Crn 0.025%, 45 g OP Crn 0.075%, 45 g OP	Zostrix Zostrix HP	2023
Carbimazole	Tab 5 mg	Neo-Mercazole	2025

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Cefalexin	Grans for oral liq 25 mg per ml & 50 mg per ml	Flynn	2024
Cefazolin	Inj 500 mg & 1 g vial	AFT	2023
Celecoxib	Cap 100 mg & 200 mg	Celecoxib Pfizer	2025
Cetirizine hydrochloride	Oral liq 1 mg per ml, 200 ml	Hisatclear	2024
Cetomacrogol	Crn BP, 500 g	Cetomacrogol-AFT	2024
Chloramphenicol	Eye oint 1%, 5 g OP	Devatis	2025
Cinacalcet	Tab 30 mg & 60 mg	Cinacalcet Devatis	2024
Ciprofloxacin	Eye drops 0.3%, 5 ml OP Tab 250 mg, 500 mg & 750 mg	Ciprofloxacin Teva Cipflox	2024 2023
Citalopram hydrobromide	Tab 20 mg	Celapram PSM Citalopram	2025 2024
Clarithromycin	Tab 250 mg & 500 mg	Klacid	2024
Clobetasol propionate	Crn & oint 0.05%, 30 g OP Scalp app 0.05%, 30 ml OP	Dermol	2025
Clomipramine hydrochloride	Tab 10 mg & 25 mg	Clomipramine Teva	2024
Clonidine	Patch 2.5 mg, 100 mcg per day Patch 5 mg, 200 mcg per day Patch 7.5 mg, 300 mcg per day	Mylan	2023
Clonidine hydrochloride	Tab 25 mcg Inj 150 mcg per ml, 1 ml ampoule Tab 150 mcg	Clonidine Teva Medsurge Catapres	2025 2024
Codeine phosphate	Tab 15 mg, 30 mg & 60 mg	PSM	2023
Colchicine	Tab 500 mcg	Colgout	2025
Colecalciferol	Cap 1.25 mg (50,000 iu)	Vit.D3	2023
Compound electrolytes	Powder for oral soln	Electral	2025
Crotamiton	Crn 10%, 20 g OP	Itch-soothe	2024
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2024
Cyclizine lactate	Inj 50 mg per ml, 1 ml ampoule	Hameln	2025
Cyclophosphamide	Tab 50 mg	Cylconex	2024
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2024
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	Ginet	2023
Darunavir	Tab 400 mg & 600 mg	Darunavir Mylan	2023
Desmopressin acetate	Nasal spray 10 mcg per dos, 6 ml OP	Desmopressin-PH&T	2023
Dexamethasone	Tab 0.5 mg & 4 mg	Dexmethsone	2024
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml & 2 ml ampoule	Hameln	2025
Dexamfetamine sulfate	Tab 5 mg	PSM	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Diazepam	Rectal tubes 5 mg Tab 2 mg & 5 mg	Stesolid Arrow-Diazepam	2025 2023
Diclofenac	Eye drops 0.1%, 5 ml OP	Voltaren Ophtha	2024
Diclofenac sodium	Tab EC 25 mg & 50 mg	Diclofenac Sandoz	2024
Digoxin	Tab 62.5 mcg Tab 250 mcg	Lanoxin PG Lanoxin	2025
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2025
Diltiazem hydrochloride	Cap long-acting 180 mg & 240 mg	Cardizem CD	2024
Dimethicone	Crn 5% pump bottle, 500 ml OP Lotn 4%, 200 ml OP	healthE Dimethicone 5% healthE Dimethicone 4%	2025
Diphtheria, tetanus and pertussis vaccine	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe	Boostrix	2024
Diphtheria, tetanus, pertussis and polio vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe	Infanrix IPV	2024
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-AgU polio virus, 10 mcg hepatitis B surface antigen in 0.5ml syringe	Infanrix-hexa	2024
Disulfiram	Tab 200 mg	Antabuse	2024
Docusate sodium	Tab 50 mg & 120 mg	Coloxyl	2023
Docusate sodium with sennosides	Tab 50 mg with sennosides 8 mg	Laxsol	2025
Domperidone	Tab 10 mg	Pharmacy Health	2024
Donepezil hydrochloride	Tab 5 mg & 10 mg	Donepezil-Rex	2023
Dorzolamide with timolol	Eye drops 2% with timolol 0.5%, 5 ml OP	Dortimopt	2024
Emtricitabine with tenofovir disoproxil	Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate)	Tenofovir Disoproxil Emtricitabine Mylan	2025
Emulsifying ointment	Oint BP	Emulsifying Ointment ADE	2023
Entacapone	Tab 200 mg	Comtan	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Eplerenone	Tab 25 mg & 50 mg	Inspra	2024
Erlotinib	Tab 100 mg & 150 mg	Alchemy	2023
Erythromycin (as lactobionate)	Inj 1 g	Erythromycin IV	2025
Escitalopram	Tab 10 mg & 20 mg	Escitalopram (Ethics)	2024
Etanercept	Inj 25 mg Inj 50 mg autoinjector Inj 50 mg prefilled syringe	Enbrel	2024
Ezetimibe	Tab 10 mg	Ezetimibe Sandoz	2023
Febuxostat	Tab 80 mg & 120 mg	Febuxostat multichem	2023
Felodipine	Tab long-acting 5 mg Tab long-acting 10 mg	Felo 5 ER Felo 10 ER	2024
Fentanyl	Inj 50 mcg per ml, 2ml ampoule Inj 50 mcg per ml, 10 ml ampoule Patch 12.5 mcg per hour Patch 25 mcg per hour Patch 50 mcg per hour Patch 75 mcg per hour Patch 100 mcg per hour	Boucher and Muir Fentanyl Sandoz	2024
Ferrous fumarate	Tab 200 mg (65 mg elemental)	Ferro-tab	2024
Ferrous fumarate with folic acid	Tab 310 mg (100 mg elemental) with folic acid 350 mcg	Ferro-F-Tabs	2024
Ferrous sulfate	Tab long-acting 325 mg (105 mg elemental) Oral liq 30 mg (6 mg elemental) per ml	Ferrograd Ferodan	2025
Filgrastim	Inj 300 mcg per 0.5 ml & 480 mcg per 0.5 ml	Nivestim	2024
Finasteride	Tab 5 mg	Ricit	2023
Flucloxacillin	Cap 250 mg & 500 mg Grans for oral liq 25 mg per ml Grans for oral liq 50 mg per ml Inj 1 g vial	Flucloxacillin-AFT AFT Flucil	2024 2023
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Mylan	2023
Fludrocortisone acetate	Tab 100 mcg	Florinef	2025
Fluorouracil sodium	Crn 5%, 20 g OP	Efudix	2024
Fluoxetine hydrochloride	Tab dispersible 20 mg, scored	Fluox	2025
Fluticasone	Aerosol inhaler 50 mcg, 125 mcg & 250 mcg per dose, 120 dose OP	Flixotide	2023
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose, 120 dose OP	Flixonase Hayfever & Allergy	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Fluticasone with salmeterol	Aerosol inhaler 50 mcg with salmeterol 25 mcg & 125 mcg with salmeterol 25 mcg, 120 dose OP	Seretide	2023
Folic acid	Tab 5 mg	Folic Acid Mylan	2024
Furosemide [Frusemide]	Inj 10 mg per ml, 2 ml ampoule Tab 40 mg	Furosemide-Baxter IPCA-Frusemide	2025 2024
Gabapentin	Cap 100 mg, 300 mg & 400 mg	Nupentin	2024
Glatiramer acetate	Inj 40 mg prefilled syringe	Copaxone	2025
Glibenclamide	Tab 5 mg	Daonil	2024
Gliclazide	Tab 80 mg	Glizide	2023
Glipizide	Tab 5 mg	Minidiab	2024
Glucagon hydrochloride	Inj 1 mg syringe kit	Glucagen Hypokit	2023
Glucose [Dextrose]	Inj 50%, 10 ml ampoule Inj 50%, 90 ml bottle	Biomed	2023
Glycerol	Suppos 4 g	Lax suppositories Glycerol	2025
	Liquid	healthE Glycerol BP	2023
Glyceryl trinitrate	Oint 0.2%, 30 g OP	Rectogesic	2024
Goserelin	Implant 3.6 mg & 10.8 mg, syringe	Teva	2023
Hepatitis A vaccine	Inj 1440 ELISA units in 1 ml syringe	Havrix	2024
	Inj 720 ELISA units in 0.5 ml syringe	Havrix Junior	
Hepatitis B recombinant vaccine	Inj 20 mcg per 1 ml prefilled syringe	Enerix-B	2024
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]	Inj 270 mg in 0.5 ml syringe	Gardasil 9	2024
Hydrocortisone	Inj 100 mg vial	Solu-Cortef	2024
Hydrocortisone and paraffin liquid and lanolin	Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%	DP Lotn HC	2023
Hydrocortisone butyrate	Oint 0.1%, 100 g OP	Locoid	2024
	Scalp lotn 0.1%, 100 ml OP Milky emuls 0.1%, 100 ml OP	Locoid Crelo	
Hydrocortisone with miconazole	Crn 1% with miconazole 2%, 15 g OP	Micreme H	2024
Hydroxocobalamin	Inj 1 mg per ml, 1 ml ampoule	Hydroxocobalamin Panpharma	2024
Hydroxyurea [hydroxycarbamide]	Cap 500 mg	Devatis	2023
Hyoscine butylbromide	Tab 10 mg	Buscopan	2023
	Inj 20 mg, 1 ml		

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Ibuprofen	Oral liq 20 mg per ml, 200 ml Tab long-acting 800 mg Tab 200 mg	Ethics Brufen SR Relieve	2024
Iloprost	Nebuliser soln 10 mcg per ml, 2 ml	Vebulis	2025
Imatinib mesylate	Cap 100 mg & 400 mg	Imatinib-Rex	2023
Indapamide	Tab 2.5 mg	Dapa-Tabs	2023
Ipratropium bromide	Aqueous nasal spray, 0.03%, 15 ml OP	Univent	2023
Isoniazid	Tab 100 mg	PSM	2024
Isoniazid with rifampicin	Tab 100 mg with rifampicin 150 mg Tab 150 mg with rifampicin 300 mg	Rifinah	2024
Isosorbide mononitrate	Tab 20 mg Tab long-acting 40 mg Tab long-acting 60 mg	ISMO 20 ISMO 40 Retard Duride	2023
Isotretinoin	Cap 5 mg, 10 mg & 20 mg	Oratane	2024
Ispaghula (psyllium) husk	Powder for oral soln, 500 g OP	Konsyl-D	2023
Ketoconazole	Shampoo 2%, 100 ml OP	Sebizole	2023
Labetalol	Tab 100 mg & 200 mg	Trandate	2024
Lamivudine	Tab 100 mg Tab 150 mg	Zetlam Lamivudine Alphapharm	2023
Lansoprazole	Cap 15 mg & 30 mg	Lanzol Relief	2024
Latanoprost	Eye drop 0.005%, 2.5 ml OP	Teva	2024
Latanoprost with timolol	Eye drops 0.005% with timolol 0.5%, 2.5 ml OP	Arrow - Lattim	2023
Leflunomide	Tab 10 mg & 20 mg	Arava	2023
Letrozole	Tab 2.5 mg	Letrole	2024
Levodopa with carbidopa	Tab long-acting 200 mg with carbidopa 50 mg Tab 100 mg with carbidopa 25 mg & 250 mg with carbidopa 25 mg	Sinemet CR Sinemet	2023
Levonorgestrel	Subdermal implant (2 x 75 mg rods)	Jadelle	2023
Lidocaine [Lignocaine]	Gel 2%, 11 ml urethral syringe	Instillagel lido	2025
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Ethics Lisinopril	2025
Lithium carbonate	Tab long-acting 400 mg	Priadel	2024
Loperamide hydrochloride	Cap 2 mg	Diamide Relief	2025
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg	Lopinavir/Ritonavir Mylan	2024
Loratadine	Tab 10 mg	Lorafix	2025
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Losartan potassium	Tab 12.5 mg, 25 mg, 50 mg & 100 mg	Losartan Actavis	2023
Losartan potassium with hydrochlorothiazide	Tab 50 mg with hydrochlorothiazide 12.5 mg	Arrow-Losartan & Hydrochlorothiazide	2025
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	Molaxole	2023
Magnesium sulphate	Inj 2 mmol per ml, 5 ml ampoule	Martindale	2023
Measles, mumps and rubella vaccine	Inj, measles virus 1,000 CCID ₅₀ , mumps virus 5,012 CCID ₅₀ , Rubella virus 1,000 CCID ₅₀ ; prefilled syringe/ampoule of diluent 0.5 ml	Priorix	2024
Mebendazole	Tab 100 mg	Vermox	2024
Mebeverine hydrochloride	Tab 135 mg	Colofac	2023
Melatonin	Tab modified-release 2 mg	Vigisom	2024
Meningococcal (groups A, C, Y and W-135) conjugate vaccine	Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial	Menactra	2024
Mercaptopurine	Tab 50 mg	Puri-nethol	2025
Mesalazine	Tab long-acting 500 mg	Pentasa	2023
Metformin hydrochloride	Tab immediate-release 500 mg	Metformin Viatris	2025
Methadone	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	Biodone Biodone Forte Biodone Extra Forte	2024
Methadone hydrochloride	Tab 5 mg	Methadone BNM	2025
Methenamine (hexamine) hippurate	Tab 1 g	Hiprex	2025
Methotrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 50 ml vial	Trexate Methotrexate Ebewe	2024 2023
Methylprednisolone aceponate	Crn & oint 0.1%, 15 g OP	Advantan	2023
Metoclopramide	Inj 5 mg per ml, 2 ml ampoule	Baxter	2025
Metoclopramide hydrochloride	Tab 10 mg	Metoclopramide Actavis 10	2023
Metoprolol tartrate	Tab 50 mg & 100 mg	IPCA-Metoprolol	2024
Metronidazole	Tab 200 mg & 400 mg	Metrogyl	2023
Metyrapone	Cap 250 mg	Metopirone	2023
Miconazole	Oral gel 20 mg per g, 40 g OP	Decozol	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Miconazole nitrate	Crn 2%, 15 g OP Vaginal crm 2% with applicator, 40 g OP	Multichem Micreme	2023
Mirtazapine	Tab 30 mg & 45 mg	Noumed	2024
Moclobemide	Tab 150 mg & 300 mg	Aurorix	2024
Modafinil	Tab 100 mg	Modavigil	2024
Mometasone furoate	Crn 0.1%, 15 g OP Crn 0.1%, 50 g OP Oint 0.1%, 15 g OP Oint 0.1%, 50 g OP Lotn 0.1%, 30 ml OP	Elocon Alcohol Free Elocon	2024
Montelukast	Tab 4 mg, 5 mg & 10 mg	Montelukast Mylan	2025
Morphine sulphate	Inj 5 mg per ml, 1 ml ampoule Inj 10 mg per ml, 1 ml ampoule Inj 15 mg per ml, 1 ml ampoule Inj 30 mg per ml, 1 ml ampoule Tab immediate-release 10 mg & 20 mg	Medsurge Sevredol	2025 2023
Moxifloxacin	Tab 400 mg	Avelox	2023
Multivitamins	Tab (BPC cap strength)	Mvite	2025
Nadolol	Tab 40 mg & 80 mg	Nadolol BNM	2024
Naloxone hydrochloride	Inj 400 mcg per ml, 1 ml ampoule	Hamelin	2024
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	2023
Naproxen	Tab 250 mg Tab 500 mg Tab long-acting 750 mg Tab long-acting 1 g	Noflam 250 Noflam 500 Naprosyn SR 750 Naprosyn SR 1000	2024
Neostigmine metilsulfate	Inj 2.5 mg per ml, 1 ml ampoule	Max Health	2024
Nevirapine	Tab 200 mg	Nevirapine Alphapharm	2024
Nitrofurantoin	Tab 50 mg & 100 mg Cap modified-release 100 mg	Nifuran Macrobid	2024 2023
Norethisterone	Tab 350 mcg	Noriday 28	2024
Nystatin	Oral liq 100,000 u per ml, 24 ml OP Vaginal crm 100,000 u per 5 g with applicator(s), 75 g OP	Nilstat	2023
Octreotide	Inj 50 mcg per ml, 1 ml ampoule Inj 100 mcg per ml, 1 ml ampoule Inj 500 mcg per ml, 1 ml ampoule	Max Health	2024
Octreotide long-acting	Inj depot 10 mg, 20 mg & 30 mg prefilled syringe	Octreotide Depot Teva	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Oestriol	Crm 1 mg per g with applicator, 15 g OP	Ovestin	2023
	Pessaries 500 mcg Tab 2 mg	Ovestin	
Oil in water emulsion	Crm, 500 g	Fatty Cream AFT	2024
Olanzapine	Orodispersible tab 5 mg & 10 mg	Zypine ODT	2023
	Tab 2.5 mg, 5 mg and 10 mg	Zypine	
Olopatadine	Eye drops 0.1%, 5 ml OP	Olopatadine Teva	2025
Omeprazole	Inj 40 mg ampoule with diluent	Dr Reddy's Omeprazole	2025
	Cap 10 mg	Omeprazole actavis 10	2023
	Cap 20 mg	Omeprazole actavis 20	
	Cap 40 mg	Omeprazole actavis 40	
Ondansetron	Tab disp 4 mg & 8 mg	Ondansetron ODT- DRLA	2023
Ornidazole	Tab 500 mg	Arrow-Ornidazole	2024
Orphenadrine citrate	Tab 100 mg	Norflex	2024
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml and 2 ml ampoule	Hameln	2024
	Inj 50 mg per ml, 1 ml ampoule		
	Tab controlled-release 5 mg, 10 mg, 20 mg, 40 mg & 80 mg	Oxycodone Sandoz	
	Cap immediate-release 5 mg, 10 mg & 20 mg Oral liq 5 mg per 5 ml	OxyNorm	
Oxytocin with ergometrine maleate	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule	Syntometrine	2025
Pancreatic enzyme	Cap prancratin 150 mg (amylase 8,000 Ph Eur U lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)	Creon 10000	2024
	Cap prancratin 300 mg (amylase 18,000 Ph Eur U lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U)	Creon 25000	
Paracetamol	Tab 500 mg-bottle pack	Noumed Paracetamol	2024
	Tab 500 mg-blisters pack	Pacimol	
	Oral liq 120 mg per 5 ml	Paracare	2023
	Oral liq 250 mg per 5 ml	Paracare Double Strength	
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 8 mg	Paracetamol + Codeine	2025
Paroxetine	Tab 20 mg	Loxamine	2025
Perindopril	Tab 2 mg & 4 mg	Coversyl	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Permethrin	Crn 5%, 30 g OP Lotn 5%, 30 ml OP	Lyderm A-Scabies	2023
Pethidine hydrochloride	Tab 50 mg	PSM	2024
Phenoxyethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml & 250 mg per 5 ml	AFT	2025
	Cap 250 mg	Cilicaine VK	2024
	Cap 500 mg		
Pimecrolimus	Crn 1%, 15 g OP	Elidel	2023
Pine tar with trolamine laurilsulfate and fluorescein	Soln 2.3% with trolamine laurilsulfate and fluorescein sodium	Pinetarsol	2023
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Vexazone	2024
Pneumococcal (PCV10) conjugate vaccine	Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe	Synflorix	2024
Pneumococcal (PPV23) polysaccharide vaccine	Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)	Pneumovax 23	2024
Poliomyelitis vaccine	Inj 80D antigen units in 0.5 ml syringe	IPOL	2024
Poloxamer	Oral drops 10%, 30 ml OP	Coloxyl	2023
Potassium iodate	Tab 253 mcg (150 mcg elemental iodine)	NeuroTabs	2023
Povidone iodine	Antiseptic solution 10%, 100 ml	Riodone Betadine	2024
	Oint 10%, 65 g OP		2023
Pramipexole hydrochloride	Tab 0.25 mg & 1 mg	Ramiprex	2025
Pravastatin	Tab 20 mg & 40 mg	Pravastatin Mylan	2023
Prednisolone	Oral liq 5 mg per ml, 30 ml OP	Redipred	2024
Prochlorperazine	Tab 5 mg	Nausafix	2023
Promethazine hydrochloride	Tab 10 mg & 25 mg	Allersoothe	2025
Propranolol	Tab 10 mg	Drofate IPCA-Propranolol	2024
	Tab 40 mg		
Pyridoxine hydrochloride	Tab 25 mg	Vitamin B6 25	2023
Quetiapine	Tab 25 mg, 100 mg, 200 mg & 300 mg	Quetapel	2023
Quinapril	Tab 5 mg	Arrow-Quinapril 5	2024
	Tab 10 mg	Arrow Quinapril 10	
	Tab 20 mg	Arrow-Quinapril 20	
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg	Accuretic 10	2024
	Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 20	

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Rifampicin	Cap 150 mg & 300 mg Oral liq 100 mg per 5 ml	Rifadin	2023
Rifaximin	Tab 550 mg	Xifaxan	2023
Riluzole	Tab 50 mg	Rilutek	2024
Risperidone	Tab 0.5 mg, 1 mg, 2 mg, 3 mg & 4 mg Oral liq 1 mg per ml	Risperidone (Teva) Risperon	2023
Rituximab	Inj 100 mg per 10 ml vial & 500 mg per 50 ml vial	Riximyo	30/09/2023
Rivastigmine	Patch 4.6 mg per 24 hour Patch 9.5 mg per 24 hour	Rivastigmine Patch BNM 5 Rivastigmine Patch BNM 10	2024
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	2023
Ropinirole hydrochloride	Tab 0.25 mg, 1 mg, 2 mg & 5 mg	Ropin	2025
Rosuvastatin	Tab 5 mg, 10 mg, 20 mg and 40 mg	Rosuvstatin Viatrix	2023
Rotavirus oral vaccine	Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator	Rotarix	2024
Salbutamol	Oral liq 400 mcg per ml, 150 ml Nebuliser soln 1 mg per ml, 2.5 ml ampoule Nebuliser soln 2 mg per ml, 2.5 ml ampoule	Ventolin Asthalin	2024
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule	Duolin	2024
Sildenafil	Tab 25 mg, 50 mg & 100 mg	Vedafil	2024
Simvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Simvastatin Mylan	2023
Sodium chloride	Inj 0.9%, 5 ml, 10 ml & 20 ml ampoule	Fresenius Kabi	2025
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2023
Sodium cromoglicate	Eye drops 2%, 10 ml OP	Allerfix	2025
Sodium fusidate [Fusidic acid]	Crn 2%, 5 g OP Oint 2%, 5 g OP	Foban	2024
Sodium hyaluronate [hyaluronic acid]	Eye drops 1 mg per ml, 10 ml OP	Hylo-Fresh	2024
Solifenacin succinate	Tab 5 mg & 10 mg	Solifenacin Mylan	2024
Somatropin (Omnitrope)	Inj 5 mg, 10 mg & 15 mg cartridge	Omnitrope	2024
Sotalol	Tab 80 mg & 160 mg	Mylan	2025
Spironolactone	Tab 25 mg & 100 mg	Spiractin	2025
Sumatriptan	Tab 50 mg & 100 mg	Sumagran	2024
Sunitinib	Cap 12.5 mg, 25 mg & 50 mg	Sunitinib Pfizer	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Tacrolimus	Oint 0.1%, 30 g OP	Zematop	2023
Taliglucerase alfa	Inj 200 unit vial	Elelyso	2023
Tamoxifen citrate	Tab 10 mg & 20 mg	Tamoxifen Sandoz	2023
Tamsulosin	Cap 400 mcg	Tamsulosin-Rex	2025
Temazepam	Tab 10 mg	Normison	2023
Tenofovir disoproxil	Tab 245 mg (300 mg as a maleate)	Tenofovir Disoproxil Mylan	2025
Tenoxicam	Tab 20 mg	Tilcotil	2025
Terbinafine	Tab 250 mg	Deolate	2023
Teriflunomide	Tab 14 mg	Aubagio	2023
Ticagrelor	Tab 90 mg	Ticagrelor Sandoz	2024
Timolol	Eye drops 0.25% & 0.5%, 5 ml OP	Arrow-Timolol	2023
Tobramycin	Inj 40 mg per ml, 2 ml vial Solution for inhalation 60 mg per ml, 5 ml	Tobramycin Mylan Tobramycin BNM	2024 2023
Tramadol hydrochloride	Cap 50 mg Tab sustained-release 100 mg Tab sustained-release 150 mg Tab sustained-release 200 mg	Arrow-Tramadol Tramal SR 100 Tramal SR 150 Tramal SR 200	2023
Travoprost	Eye drops 0.004%, 2.5 ml OP	Travatan	2024
Tretinoin	Crn 0.5 mg per g, 50 g OP	ReTrieve	2024
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml ampoule Inj 40 mg per ml, 1 ml ampoule Paste 0.1%, 5 g OP Crn & oint 0.02%, 100 g OP	Kenacort-A 10 Kenacort-A 40 Kenalog in Orabase Aristocort	2023
Trimethoprim	Tab 300 mg	TMP	2024
Trimethoprim with sulphamethoxazole [co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	Trisul	2024
Tuberculin PPD [Mantoux] test	Inj 5 TU per 0.1 ml, 1 ml vial	Tubersol	2024
Ursodeoxycholic acid	Cap 250 mg	Ursosan	2023
Valaciclovir	Tab 500 mg & 1,000 mg	Valclovir	2024
Valganciclovir	Tab 450 mg	Valganciclovir Mylan	2024
Vancomycin	Inj 500 mg vial	Mylan	2023
Varenicline tartrate	Tab 0.5 mg x 11 and 1 mg x 42, 53 OP Tab 1 mg	Varenicline Pfizer	2024
Varicella vaccine [Chickenpox vaccine]	Inj 1350 PFU prefilled syringe	Varivax	2024
Water	Inj 20 ml ampoule	Fresenius Kabi	2025

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to March 2023

Generic Name	Presentation	Brand Name	Expiry Date*
Zoledronic acid	Inj 4 mg per 5 ml, vial	Zoledronic Acid Mylan	2024
Zopiclone	Tab 7.5 mg	Zopiclone Actavis	2024

March 2023 changes are in bold type

**Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.*

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 March 2023

6 CALCIUM CARBONATE
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml)
– Subsidy by Endorsement.....47.30 473 ml ✓ **Calcium Carbonate PAI**
Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate and the prescription is endorsed accordingly.

7 HYDROCORTISONE ACETATE
Rectal foam 10%, CFC-Free (14 applications).....26.55 15 g OP ✓ **Colifoam**
Note – this is the listing of a new pack size.

11 LIRAGLUTIDE – Special Authority see SA2187 – Retail pharmacy
a) Maximum of 9 inj per prescription
b) Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist.
c) Maximum of 1 pack of 3 (6 mg per ml, 3 ml) prefilled pens will be funded per month
Inj 6 mg per ml, 3 ml prefilled pen383.72 3 ✓ **Victoza**

► SA2187 Special Authority for subsidy
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1. Patient has previously received an initial Special Authority approval for either an SGLT-2 inhibitor or GLP-1 agonist; or
2. All of the following:
 - 2.1 Patient has type 2 diabetes; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 2.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 2.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 2.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 2.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 2.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent eg metformin, vildagliptin, or insulin) for at least 3 months.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (ie angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause

37 FOLIC ACID
* Tab 5 mg.....5.82 100 ✓ **Folic Acid Viatrix**

49 MIDODRINE – Special Authority see SA1474 – Retail pharmacy
Tab 2.5 mg.....38.23 100 ✓ **Midodrine Medsurge**
Tab 5 mg.....59.98 100 ✓ **Midodrine Medsurge**

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

New Listings – effective 1 March 2023 (continued)

50	METOPROLOL TARTRATE * Inj 1 mg per ml, 5 ml vial	26.50	5	✓ Metoprolol IV Viatrix
54	PRAVASTATIN * Tab 20 mg	2.11	28	✓ Pravastatin Viatrix
55	SIMVASTATIN * Tab 40 mg	3.58	90	✓ Simvastatin Viatrix
64	HYDROCORTISONE * Crm 1% – Only on a prescription	20.40	500 g	✓ Noumed
74	ETHINYLLOESTRADIOL WITH LEVONORGESTREL * Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – Up to 112 tab available on a PSO	1.50	84	✓ Lo-Oralcon 20 ED
	* Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – Up to 112 tab available on a PSO	1.50	84	✓ Oralcon 30 ED
94	CLINDAMYCIN Inj 150 mg per ml, 4 ml ampoule	35.10	10	✓ Hameln
127	PETHIDINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Tab 50 mg	8.68	10	✓ Noumed Pethidine
134	ONDANSETRON * Tab 4 mg	2.27	50	✓ Periset
	* Tab 8 mg	4.10	50	✓ Periset
134	CLOZAPINE – Hospital pharmacy [HP4] Safety medicine; prescriber may determine dispensing frequency Tab 25 mg	6.69	50	✓ Clozaril
	Tab 100 mg	17.33	50	✓ Clozaril
Note – These are the listing of new Pharmacodes 2633353 and 2633361 respectively.				
170	OCTREOTIDE Inj 100 mcg per ml, 1 ml ampoule	32.71	5	✓ Octreotide GH S29 Wastage claimable
254	PHARMACY SERVICES May only be claimed once per patient. * Brand switch fee	4.50	1 fee	✓ BSF Ticagrelor Sandoz ✓ BSF Vebulis ✓ BSF Celapram

The Pharmacode for BSF Ticagrelor Sandoz is 2653206

The Pharmacode for BSF Vebulis is 2653214

The Pharmacode for BSF Celapram is 2653222

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings – effective 1 March 2023 (continued)

283	INFLUENZA VACCINE Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) – [Xpharm]	11.00	1	✓ Afluria Quad Junior (2023 formulation)
	a) Access criteria apply Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	110.00	10	✓ Afluria Quad (2023 formulation)
	a) Only on a prescription b) No patient co-payment payable c) Access criteria apply			
288	ROTAVIRUS ORAL VACCINE – [Xpharm] Maximum of two doses for patients meeting the following: 1) first dose to be administered in infants aged under 14 weeks of age; and 2) no vaccination being administered to children aged 24 weeks or over. Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube	0.00	10	✓ Rotarix

Effective 1 February 2023

9	OMEPRAZOLE * Inj 40 mg ampoule with diluent	37.38	5	✓ Ocicure S29 Wastage claimable
98	KETOCONAZOLE Tab 200 mg – PCT	CBS	30	✓ Burel S29

Effective 20 January 2023

131	PREGABALIN Note: Not subsidised in combination with subsidised gabapentin Cap 150 mg	12.44	56	✓ Milpharm S29 Wastage claimable
-----	--	-------	----	--

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions, Chemical Names and Presentations Effective 1 March 2023

6	SODIUM ALGINATE (brand name change) * Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80 (13.61)	60		Gaviscon Double Extra Strength
15	Insulin Syringes and Needles (amended note) Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or liraglutide or when prescribed for an insulin patient and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or liraglutide .				
26	GLYCEROL (amended presentation description) * Suppos 2.8/4.0 g 4-g – Only on a prescription	10.39	20	✓	Lax-suppositories Glycerol
40	TICAGRELOR – Special Authority see SA1955 – Retail pharmacy (addition of brand switch fee) Brand switch fee payable (Pharmacode 2653206) * Tab 90 mg.....	23.85	56	✓	Ticagrelor Sandoz
47	QUINAPRIL (reinstate stat dispensing) * Tab 5 mg..... * Tab 10 mg..... * Tab 20 mg.....	5.97 5.18 7.95	90 90 90	✓	Arrow-Quinapril 5 Arrow-Quinapril 10 Arrow-Quinapril 20
50	PROPRANOLOL (reinstate stat dispensing) * Tab 10 mg.....	7.04	100	✓	Drofate
59	ILOPROST – Special Authority see SA1705 – Retail pharmacy (addition of brand switch fee) Brand switch fee payable (Pharmacode 2653214) Nebuliser soln 10 mcg per ml, 2 ml.....	185.03	30	✓	Veblus
79	ZOLEDRONIC ACID (Special Authority criteria removed) Inj 4 mg per 5 ml, vial – Special Authority see SA2109 – Retail pharmacy	18.00	1	✓	Zoledronic acid Mylan Zoledronic acid Viatris

► SA2109 – Special Authority for Subsidy

Initial application – (bone metastases) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1 Patient has hypercalcaemia of malignancy; or

2 Both:

2.1 Patient has bone metastases or involvement; and

2.2 Patient has severe bone pain resistant to standard first-line treatments; or

3 Both:

3.1 Patient has bone metastases or involvement; and

3.2 Patient is at risk of skeletal-related events pathological fracture, spinal cord compression, radiation to bone or surgery to bone.

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 March 2023 (continued)

continued...

Initial application — (early breast cancer*) from any relevant practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1— Treatment to be used as adjuvant therapy for early breast cancer; and
- 2— Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
- 3— Treatment to be administered at a minimum interval of 6-monthly for a maximum of 3 years.

Note: Indications marked with * are unapproved indications.

Initial application — (symptomatic hypercalcaemia*) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has symptomatic hypercalcaemia.

Note: Indications marked with * are unapproved indications.

94	CLINDAMYCIN (amended presentation description) Inj phosphate 150 mg per ml, 4 ml ampoule.....	35.10 39.00	10	✓ Hameln ✓ Dalacin C
114	ZOLEDRONIC ACID (Special Authority criteria removed) Inj 0.05 mg per ml, 100 ml, bag — Special Authority see SA2110—Retail pharmacy.....	22.53	100 ml OP	✓ Zoledronic Acid Viatrix ✓ Zoledronic-US S29
	Inj 0.05 mg per ml, 100 ml, vial — Special Authority see SA2110—Retail pharmacy.....	60.00	100 ml OP	✓ Aclasta

▶ SA2110—Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1— Paget's disease; and
- 2— Any of the following:
 - 2.1— Bone or articular pain; or
 - 2.2— Bone deformity; or
 - 2.3— Bone, articular or neurological complications; or
 - 2.4— Asymptomatic disease, but risk of complications; or
 - 2.5— Preparation for orthopaedic surgery; and
- 3— The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1— Any of the following:
 - 1.1— History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2— History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3— History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4— Documented T-Score less than or equal to -3.0 (see Note); or
 - 1.5— A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or

continued...

Changes to Restrictions – effective 1 March 2023 (continued)

continued...

1-6 Patient has had a Special Authority approval for alendronate (Underlying cause — Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initial application — (Underlying cause — glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause — glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period. The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period. The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause — osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Changes to Restrictions – effective 1 March 2023 (continued)

continued...

1.6 The patient has had a Special Authority approval for alendronate (Underlying was glucocorticosteroid therapy but patient now meets the 'Underlying cause – Osteoporosis' criteria) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initial application — (spinal cord injury*) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1 Patient has experienced an acute traumatic spinal cord injury in the last six months; and

2 Patient is being managed by a specialist spinal acute care and rehabilitation unit; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Note: Indications marked with * are unapproved indications.

Renewal — (spinal cord injury*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period; and

2 The patient has not received more than two doses of zoledronic acid for this indication.

The patient must not have had more than 1 prior approval.


Notes: No further renewals will be subsidised. A maximum of 2 vials of zoledronic acid treatment for spinal cord injury will be subsidised. Indications marked with * are unapproved indications.

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

128	CITALOPRAM HYDROBROMIDE (addition of brand switch fee) Brand switch fee payable (Pharmacode 2653222)			
	* Tab 20 mg.....	2.86	84	✓ <u>Celapram</u>
146	DISULFIRAM (removal of s29 and wastage claimable)			
	Tab 200 mg.....	236.40	100	✓ <u>Antabuse</u> 
	Wastage claimable			

Changes to Restrictions – effective 1 March 2023 (continued)

285 MENINGOCOCCAL B MULTICOMPONENT VACCINE – [Xpharm] (amended restriction criteria)

Any of the following:

A) Three doses for children up to 12 months of age (inclusive) for primary immunisation; or

B) Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025; or

Either:

A) Both:

1) Child is under one year of age; and

2) Any of the following:

i) up to three doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or

ii) up to three doses for close contacts of meningococcal cases of any group; or

iii) up to three doses for child who has previously had meningococcal disease of any group; or

iv) up to three doses for bone marrow transplant patients; or

v) up to three doses for child pre- and post-immunosuppression*; or

C) Both:

1) Person is one year of age or over; and

2) Any of the following:

i) up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or

ii) up to two doses for close contacts of meningococcal cases of any group; or

iii) up to two doses for person who has previously had meningococcal disease of any group; or

iv) up to two doses for bone marrow transplant patients; or

v) up to two doses for person pre- and post-immunosuppression*; or

D) Both:

1) Person is aged between 13 and 25 years (inclusive); and

2) Either:

i) **Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or**

ii) **Two doses for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 March 2023 to 28 February 2024.**

*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 175 mcg per 0.5 ml prefilled syringe 0.00 1 ✓ **Bexero**

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 March 2023

6	SODIUM ALGINATE (↑ price but not subsidy) * Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80 (13.61)	60		Gaviscon Extra Strength
40	DIPYRIDAMOLE (↑ subsidy) * Tab long-acting 150 mg.....	13.93	60	✓	Pytazen SR
45	COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] (↑ subsidy) Soln with electrolytes (2 × 500 ml)	8.55	1,000 ml OP	✓	Pedialyte - Bubblegum
48	FLECAINIDE ACETATE (↓ subsidy) ▲ Cap long-acting 100 mg	35.78	90	✓	Flecainide Controlled Release Teva
	▲ Cap long-acting 200 mg	54.28	90	✓	Flecainide Controlled Release Teva
48	FLECAINIDE ACETATE (↑ subsidy) Inj 10 mg per ml, 15 ml ampoule	104.00	5	✓	Tambacor
56	GLYCERYL TRINITRATE (↑ subsidy) * Oral pump spray, 400 mcg per dose – Up to 250 dose available on a PSO	7.48	250 dose OP	✓	Nitrolingual Pump Spray
62	ECONAZOLE NITRATE (↑ price but not subsidy) Crm 1%	1.00 (7.78)	20 g OP		Pevaryl
	a) Only on a prescription b) Not in combination Foaming soln 1%, 10 ml sachets	9.89 (17.92)	3		Pevaryl
	a) Only on a prescription b) Not in combination				
66	WOOL FAT WITH MINERAL OIL – Only on a prescription (↑ price but not subsidy) * Lotn hydrous 3% with mineral oil	5.60 (14.96)	1,000 ml		DP Lotion
		1.40 (5.87)	250 ml OP		DP Lotion
92	ROXITHROMYCIN (↓ subsidy) Tab 150 mg..... Tab 300 mg.....	13.19 25.00	50 50	✓	Arrow-Roxithromycin Arrow-Roxithromycin
94	TETRACYCLINE – Special Authority see SA1332 – Retail pharmacy (↑ subsidy) Tab 250 mg.....	58.20	28	✓	Accord

Check your Schedule for full details Schedule page ref		Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✔ fully subsidised
---	--	---------------------------------	-----	--

Changes to Subsidy and Manufacturer's Price – effective 1 March 2023 (continued)

110	PYRIDOSTIGMINE BROMIDE († subsidy) ▲ Tab 60 mg.....	50.28	100	✔ Mestinon
246	THEOPHYLLINE († subsidy) * Tab long-acting 250 mg..... * Oral liq 80 mg per 15 ml.....	23.94 17.62	100 500 ml	✔ Nuelin-SR ✔ Nuelin
248	MASK FOR SPACER DEVICE († subsidy) a) Up to 50 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Small.....	2.70	1	✔ e-chamber Mask
248	SPACER DEVICE († subsidy) a) Up to 50 dev available on a PSO b) Only on a PSO 220 ml (single patient)..... 510 ml (single patient).....	3.65 5.95	1 1	✔ e-chamber Turbo ✔ e-chamber La Grande

Effective 1 February 2023

152	CYTARABINE († subsidy) Inj 1 mg for ECP – PCT only – Specialist..... Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist.....	0.29 94.40	10 mg 100 mg OP	✔ Baxter ✔ Baxter
155	DACARBAZINE – PCT only – Specialist († subsidy) Inj 200 mg for ECP.....	72.11	200 mg OP	✔ Baxter
155	DAUNORUBICIN – PCT only – Specialist († subsidy) Inj 20 mg for ECP.....	171.93	20 mg OP	✔ Baxter

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 March 2023

35	SODIUM FLUORIDE * Tab 1.1 mg (0.5 mg elemental).....	8.64	100	✓ PSM
41	TICAGRELOR – Special Authority see SA1955 – Retail pharmacy * Tab 90 mg.....	90.00	56	✓ Brilinta
53	EPLERENONE – Special Authority see SA1728 – Retail pharmacy Tab 25 mg..... Note – this delist applies to Pharmacode 2316129.	18.50	30	✓ Inspra
57	AMBRISENTAN – Special Authority see SA1702 – Retail pharmacy Tab 10 mg.....	1,550.00	30	✓ Ambrisentan Mylan
60	ILOPROST – Special Authority see SA1705 – Retail pharmacy Nebuliser soln 10 mcg per ml, 2 ml.....	740.10	30	✓ Ventavis
65	CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%	2.35 3.10	500 ml OP 1,000 ml OP	✓ Boucher ✓ Boucher
80	TETRACOSACTRIN * Inj 250 mcg per ml, 1 ml ampoule	75.00	1	✓ AU Synacthen
91	ROXITHROMYCIN Tab disp 50 mg	8.29	10	✓ Rulide D Restricted to children under 12 years of age.
123	MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.99	5	✓ DBL Morphine Sulphate
	Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	5.61	5	✓ DBL Morphine Sulphate
	Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	7.08	5	✓ DBL Morphine Sulphate
	Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	7.28	5	✓ DBL Morphine Sulphate
125	CITALOPRAM HYDROBROMIDE * Tab 20 mg.....	1.91	84	✓ PSM Citalopram
130	AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency Tab 400 mg..... Note – this delist applies to Pharmacode 2500159.	29.78	60	✓ Sulprix
241	SODIUM CROMOGLICATE Eye drops 2%	1.79	5 ml OP	✓ Rexacrom

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	---

Delisted Items – effective 1 March 2023 (continued)

266	FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 – Retail pharmacy			
	Powder (unflavoured)	35.50	300 g OP	✓ KetoCal 4:1
	Powder (vanilla).....	35.50	300 g OP	✓ KetoCal 4:1
	Note – this delist applies to Pharmacodes, 2439778 (unflavoured) and 2400529 (vanilla).			
283	INFLUENZA VACCINE			
	Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)			
	– [Xpharm]	11.00	1	✓ Afluria Quad Junior (2022 formulation)
	Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	110.00	10	✓ Afluria Quad (2022 formulation)

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 June 2023

254	PHARMACY SERVICES May only be claimed once per patient. * Brand switch fee.....	4.50	1 fee	✓ BSF Ticagrelor Sandoz ✓ BSF Vebulis ✓ BSF Celapram
	The Pharmacode for BSF Ticagrelor Sandoz is 2653206 The Pharmacode for BSF Vebulis is 2653214 The Pharmacode for BSF Celapram is 2653222			

61	HYDROGEN PEROXIDE * Crm 1%.....	8.56	15 g OP	✓ Crystaderm
----	------------------------------------	------	---------	---------------------

Effective 1 July 2023

98	KETOCONAZOLE Tab 200 mg – PCT.....	CBS	100	✓ Strides Shasun S29
	Note – delisting revoked.			

Effective 1 August 2023

11	METFORMIN HYDROCHLORIDE * Tab immediate-release 500 mg.....	14.74	1,000	✓ Metformin Mylan
49	MIDODRINE – Special Authority see SA1474 – Retail pharmacy Tab 2.5 mg..... Tab 5 mg.....	53.00 79.00	100 100	✓ Gutron ✓ Gutron
53	INDAPAMIDE * Tab 2.5 mg.....	11.61	100	✓ Mylan Indapamide S29
64	HYDROCORTISONE * Crm 1% – Only on a prescription.....	17.15	500 g	✓ Hydrocortisone (PSM)
74	ETHINYLLOESTRADIOL WITH LEVONORGESTREL * Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – Up to 112 tab available on a PSO..... 6.45	2.18 6.45	84 112	✓ Microgynon 20 ED ✓ Femme-Tab ED
	* Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – Up to 112 tab available on a PSO..... 6.45	1.77 6.45	84 112	✓ Levlen ED ✓ Femme-Tab ED
94	CLINDAMYCIN Inj 150 mg per ml, 4 ml ampoule.....	39.00	10	✓ Dalacin C
97	FLUCONAZOLE Cap 50 mg.....	2.75	28	✓ Dizole

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Items to be Delisted – effective 1 August 2023 (continued)

107	DARUNAVIR – Special Authority see SA2139 – Retail pharmacy Tab 600 mg.....	196.65	60	✓ Darunavir Mylan
127	PETHIDINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Tab 50 mg.....	4.70	10	✓ PSM
131	PHENYTOIN SODIUM Cap 30 mg Cap 100 mg	74.00 37.00	200 200	✓ Dilantin ✓ Dilantin
Note – these delistings relate to Pharmacodes 2550229 and 2552140 respectively.				
134	ONDANSETRON * Tab 4 mg..... * Tab 8 mg.....	2.68 4.57	50 50	✓ Onrex ✓ Onrex

Effective 1 March 2024

251	TIMOLOL * Eye drops 0.5%, gel forming	3.78	2.5 ml OP	✓ Timoptol XE
251	DORZOLAMIDE HYDROCHLORIDE * Eye drops 2%	9.77 (17.44)	5 ml OP	Trusopt

Effective 1 October 2024

162	VINORELBINE – PCT only – Specialist Inj 10 mg per ml, 1 ml vial	12.00	1	✓ Navelbine
	Inj 10 mg per ml, 5 ml vial	56.00	1	✓ Navelbine

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Index

Pharmaceuticals and brands

A

Aclasta	26
Afluria Quad (2022 formulation)	33
Afluria Quad (2023 formulation)	24
Afluria Quad Junior (2022 formulation)	33
Afluria Quad Junior (2023 formulation)	24
Ambrisentan	32
Ambrisentan Mylan	32
Amisulpride.....	32
Antabuse	28
Arrow-Quinapril 5	25
Arrow-Quinapril 10.....	25
Arrow-Quinapril 20.....	25
Arrow-Roxithromycin	30
AU Synacthen	32

B

Bexsero	29
Brilinta	32
BSF Celapram	23, 34
BSF Ticagrelor Sandoz	23, 34
BSF Vebulis.....	23, 34

C

Calcium carbonate	22
Calcium Carbonate PAI.....	22
Celapram	28
Cetomacrogol with glycerol.....	32
Citalopram hydrobromide.....	28, 32
Clindamycin.....	23, 26, 34
Clozapine	23
Clozaril	23
Colifoam	22
Compound electrolytes with glucose [Dextrose]....	30
Crystaderm.....	34
Cytarabine	31

D

Dacarbazine	31
Dalacin C	26, 34
Darunavir	35
Darunavir Mylan.....	35
Daunorubicin	31
DBL Morphine Sulphate.....	32
Dextrose	30
Dilantin	35
Dipyridamole.....	30
Disulfiram	28
Dizole	34
Dorzolamide hydrochloride.....	35
DP Lotion.....	30
Drofate.....	25

E

e-chamber La Grande.....	31
e-chamber Mask.....	31
e-chamber Turbo	31
Econazole nitrate.....	30
Eplerenone.....	32
Ethinylloestradiol with levonorgestrel	23, 34

F

Fat low carbohydrate formula	33
Femme-Tab ED	34
Flecainide acetate.....	30
Flecainide Controlled Release Teva.....	30
Fluconazole.....	34
Folic acid	22
Folic Acid Viatris	22

G

Gaviscon Double Strength	25
Gaviscon Extra Strength	25, 30
Glycerol	25
Glyceryl trinitrate.....	30
Gutron	34

H

Hydrocortisone	23, 34
Hydrocortisone acetate	22
Hydrocortisone (PSM).....	34
Hydrogen peroxide	34

I

Iloprost	25, 32
Indapamide	34
Influenza vaccine.....	24, 33
Inspra	32

K

KetoCal 4:1	33
Ketoconazole	24, 34

L

Lax-suppositories Glycerol	25
Levlen ED	34
Liraglutide.....	22
Lo-Oralcon 20 ED	23

M

Mask for spacer device	31
Meningococcal B multicomponent vaccine	29
Mestinon.....	31
Metformin hydrochloride	34
Metformin Mylan	34
Metoprolol IV Viatris	23
Metoprolol tartrate.....	23
Microgynon 20 ED	34
Midodrine	22, 34
Midodrine Medsurge	22

Index

Pharmaceuticals and brands

Morphine sulphate.....	32	Rotavirus oral vaccine	24
Mylan Indapamide.....	34	Roxithromycin.....	30, 32
N		Rulide D.....	32
Navelbine.....	35	S	
Nitrolingual Pump Spray.....	30	Simvastatin.....	23
Noumed Pethidine.....	23	Simvastatin Viatrix.....	23
Nuelin.....	31	Sodium alginate.....	25, 30
Nuelin-SR.....	31	Sodium cromoglicate.....	32
O		Sodium fluoride.....	32
Ocicure.....	24	Spacer device.....	31
Octreotide.....	23	Strides Shasun.....	34
Octreotide GH.....	23	Sulprix.....	32
Omeprazole.....	24	T	
Ondansetron.....	23, 35	Tambacor.....	30
Onrex.....	35	Tetracosactrin.....	32
Oralcon 30 ED.....	23	Tetracycline.....	30
P		Theophylline.....	31
Pedialyte – Bubblegum.....	30	Ticagrelor.....	25, 32
Periset.....	23	Ticagrelor Sandoz.....	25
Pethidine hydrochloride.....	23, 35	Timolol.....	35
Pevaryl.....	30	Timoptol XE.....	35
Pharmacy services.....	23, 34	Trusopt.....	35
Phenytoin sodium.....	35	V	
Pravastatin.....	23	Veibulis.....	25
Pravastatin Viatrix.....	23	Ventavis.....	32
Pregabalin.....	24	Victoza.....	22
Propranolol.....	25	Vinorelbine.....	35
PSM Citalopram.....	32	W	
Pyridostigmine bromide.....	31	Wool fat with mineral oil.....	30
Pytazen SR.....	30	Z	
Q		Zoledronic acid.....	25, 26
Quinapril.....	25	Zoledronic acid Mylan.....	25
R		Zoledronic acid Viatrix.....	25
Rexacrom.....	32	Zoledronic Acid Viatrix.....	26
Rotarix.....	24	Zoledronic-US.....	26

